Companies › Shanghai Unicar-Therapy Bio-medicine Technology
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ssCART-19 CAR-T cell therapy targeting CD19 on B-cell malignancies | CD19 | Phase 1 | B Cell Lymphoma | Jan 2027 |
| U32 CAR-T CAR-T cell therapy | – | Phase 1 | Acute Myeloid Leukaemia | Dec 2027 |
| U87 autologous CAR T-cell anti-EGFR CAR-T cell therapy | – | Phase 1 | Nasopharynx Cancer | Dec 2027 |
| U16 CAR-T cell therapy targeting CD19 | – | Phase 1 | Relapsed or Refractory Non-Hodgkin's Lymphoma | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07093073 | ssCART-19 | Phase 1 | B Cell Lymphoma | Oncology | Jan 2027 |
| NCT07036250 | U32 CAR-T | Phase 1 | Acute Myeloid Leukaemia | Oncology | Dec 2027 |
| NCT06614686 | U87 autologous CAR T-cell | Phase 1 | Nasopharynx Cancer | Oncology | Dec 2027 |
| NCT06987916 | ssCART-19 | Phase 1 | B Cell Lymphoma | Oncology | Apr 2028 |
| NCT05768529 | U16 | Phase 1 | Relapsed or Refractory Non-Hodgkin's Lymphoma | Oncology | Dec 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.